PABPC3

Across TCGA pan-cancer cohorts, PABPC3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PABPC3 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher PABPC3 Mutation is associated with better overall survival. In most high-consensus cancer types, elevated PABPC3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, SARC, and UCS are the cancer types where PABPC3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	II,III,IV	0.941	0.458	.020	18	view →
SARC	DFS	Median	All	0.126	0.613	.002	12	view →
UCS	OS	Median	All	0.185	0.686	.034	6	view →
GBM	DFS	Median	All	0.052	0.242	.011	3	view →
SKCM	OS	Median	III,IV	0.369	0.729	.034	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PABPC3–UCEC (OS)

Open the UCEC breakdown →